GMED icon

Globus Medical

71.77 USD
-0.56
0.77%
At close Apr 30, 4:00 PM EDT
After hours
71.77
+0.00
0.00%
1 day
-0.77%
5 days
0.03%
1 month
-1.95%
3 months
-22.93%
6 months
-4.40%
Year to date
-12.29%
1 year
44.15%
5 years
51.22%
10 years
200.42%
 

About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

Employees: 5,300

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

140% more first-time investments, than exits

New positions opened: 103 | Existing positions closed: 43

110% more call options, than puts

Call options by funds: $24.5M | Put options by funds: $11.7M

18% more capital invested

Capital invested by funds: $7.6B [Q3] → $9B (+$1.39B) [Q4]

11% more repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 150

11% more funds holding

Funds holding: 443 [Q3] → 492 (+49) [Q4]

6% more funds holding in top 10

Funds holding in top 10: 18 [Q3] → 19 (+1) [Q4]

1.56% more ownership

Funds ownership: 94.07% [Q3] → 95.63% (+1.56%) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$80
11%
upside
Avg. target
$93
29%
upside
High target
$103
44%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Truist Securities
Richard Newitter
57% 1-year accuracy
29 / 51 met price target
11%upside
$80
Hold
Maintained
11 Apr 2025
Barclays
Matt Miksic
48% 1-year accuracy
20 / 42 met price target
44%upside
$103
Overweight
Maintained
24 Feb 2025
Stifel
Mathew Blackman
35% 1-year accuracy
6 / 17 met price target
31%upside
$94
Buy
Maintained
21 Feb 2025
Wells Fargo
Vik Chopra
36% 1-year accuracy
4 / 11 met price target
30%upside
$93
Overweight
Maintained
21 Feb 2025

Financial journalist opinion

Based on 7 articles about GMED published over the past 30 days

Positive
Zacks Investment Research
1 week ago
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term
Neutral
Zacks Investment Research
1 week ago
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
Investors need to pay close attention to Globus Medical (GMED) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Globus Medical (GMED) Stock?
Positive
Zacks Investment Research
1 week ago
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
Neutral
GlobeNewsWire
1 week ago
Globus Medical Schedules First Quarter Earnings Release and Conference Call
AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Globus Medical Schedules First Quarter Earnings Release and Conference Call
Positive
Zacks Investment Research
2 weeks ago
International Growth Drives GMED Stock Amid Fierce Competition
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
International Growth Drives GMED Stock Amid Fierce Competition
Positive
Zacks Investment Research
3 weeks ago
GMED Stock May Benefit Following the Acquisition of Nevro
Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.
GMED Stock May Benefit Following the Acquisition of Nevro
Neutral
GlobeNewsWire
3 weeks ago
Globus Medical completes acquisition of Nevro Corp.
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain.
Globus Medical completes acquisition of Nevro Corp.
Neutral
Business Wire
1 month ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
Positive
Zacks Investment Research
1 month ago
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Positive
Zacks Investment Research
1 month ago
Should You Hold Globus Medical Stock in Your Portfolio Now?
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
Should You Hold Globus Medical Stock in Your Portfolio Now?
Charts implemented using Lightweight Charts™